{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:31:29Z","timestamp":1792697489224,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01253-5","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:05:41Z","timestamp":1741896341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-1425","authenticated-orcid":false,"given":"Jo\u00e3o Tadeu Damian","family":"Souto Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Oliveira","family":"Cantadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan de Queiroz","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"1253_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45.","journal-title":"Nat Rev Dis Primers"},{"key":"1253_CR2","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood.2020008735","volume":"139","author":"A Perrot","year":"2022","unstructured":"Perrot A. How I treat frontline transplantation-eligible multiple myeloma. Blood. 2022;139:2882\u20138.","journal-title":"Blood"},{"key":"1253_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1253_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338.","journal-title":"Lancet"},{"key":"1253_CR5","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1378\u201390.","journal-title":"Lancet Oncol"},{"key":"1253_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003\u201314.","journal-title":"Lancet Oncol"},{"key":"1253_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"1253_CR8","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825\u201337.","journal-title":"Lancet Haematol"},{"key":"1253_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl J Med. 2024;390:301\u201313.","journal-title":"N. Engl J Med"},{"key":"1253_CR10","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. Cochrane; 2023. http:\/\/www.training.cochrane.org\/handbook"},{"key":"1253_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1253_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1253_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1253_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"1253_CR15","unstructured":"Sch\u00fcnemann HJ, Bro\u017cek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group; 2013. https:\/\/guidelinedevelopment.org\/handbook"},{"key":"1253_CR16","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"1253_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"key":"1253_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111.","journal-title":"BMC Med Res Methodol"},{"key":"1253_CR19","volume":"13","author":"A Messori","year":"2021","unstructured":"Messori A. Synthetizing published evidence on survival by reconstruction of patient-level data and generation of a multi-trial Kaplan-Meier curve. Cureus. 2021;13:e19422.","journal-title":"Cureus"},{"key":"1253_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2023-187339","volume":"142","author":"NS Joseph","year":"2023","unstructured":"Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Blood. 2023;142:647\u2013647.","journal-title":"Blood"},{"key":"1253_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01120-9","volume":"14","author":"NS Joseph","year":"2024","unstructured":"Joseph NS, Kaufman JL, Gupta VA, Hofmeister CC, Dhodapkar MV, Boise LH, et al. Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood Cancer J. 2024;14:159.","journal-title":"Blood Cancer J"},{"key":"1253_CR22","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2023-191911","volume":"142","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial. Blood. 2023;142:LBA-1.","journal-title":"Blood"},{"key":"1253_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"1253_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"1253_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hern\u00e1ndez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134:1337\u201345.","journal-title":"Blood"},{"key":"1253_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol."},{"key":"1253_CR27","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:2901\u201312.","journal-title":"J Clin Oncol"},{"key":"1253_CR28","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"Lancet Haematol"},{"key":"1253_CR29","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Perrot A, Hulin C, Manier S, Macro M, Chretien M-L, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024;143:2029\u201336.","journal-title":"Blood"},{"key":"1253_CR30","doi-asserted-by":"crossref","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810\u201321","DOI":"10.1182\/blood-2021-145097"},{"key":"1253_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42:26\u201337.","journal-title":"J Clin Oncol"},{"key":"1253_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Rosi\u00f1ol L, van der Klift M, Mina R, et al. Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142:4\u20134.","journal-title":"Blood"},{"key":"1253_CR33","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"1253_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01109-4","volume":"14","author":"C Pawlyn","year":"2024","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA, Wei LJ, Davies F, Nadeem O, et al. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J. 2024;14:134.","journal-title":"Blood Cancer J"},{"key":"1253_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"1253_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35:18\u201330.","journal-title":"Leukemia"},{"key":"1253_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022269","volume":"144","author":"C Bommier","year":"2024","unstructured":"Bommier C, Maurer MJ, Lambert J. What clinicians should know about surrogate end points in hematologic malignancies. Blood. 2024;144:11\u201320.","journal-title":"Blood"},{"key":"1253_CR38","volume":"15","author":"A Messori","year":"2023","unstructured":"Messori A, Fadda V, Romeo MR, Veneziano S, Trippoli S. A comparison of statistical analysis between \u201cReal\u201d patients reported in Kaplan-Meier curves and \u201cReconstructed\u201d patients estimated through the IPDfromKM method: analysis of eight trials evaluating catheter ablation of ventricular tachycardia. Cureus. 2023;15:e47891.","journal-title":"Cureus"},{"key":"1253_CR39","doi-asserted-by":"publisher","first-page":"300060521103813","DOI":"10.1177\/03000605211038135","volume":"49","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis. J Int Med Res. 2021;49:3000605211038135.","journal-title":"J Int Med Res"},{"key":"1253_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01440-x","volume":"11","author":"S Kiss","year":"2021","unstructured":"Kiss S, Gede N, Hegyi P, Nagy B, De\u00e1k R, Dembrovszky F, et al. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2021;11:21916.","journal-title":"Sci Rep"},{"key":"1253_CR41","volume":"13","author":"T Menon","year":"2021","unstructured":"Menon T, Kataria S, Adhikari R, Khan H, Khalid MZ, Saeeduddin MO, et al. Efficacy of daratumumab-based regimens compared to standard of care in transplant-eligible multiple myeloma: a meta-analysis. Cureus. 2021;13:e15098.","journal-title":"Cureus"},{"key":"1253_CR42","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","volume":"23","author":"J Ficek","year":"2023","unstructured":"Ficek J, Kalaitzaki E, Yuan SS, Tosolini A, Du L, Kremer BE, et al. Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2023;23:e213\u201321.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1253_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103211","volume":"159","author":"LL Chong","year":"2021","unstructured":"Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103211.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1253_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jha2.46","volume":"1","author":"TW Htut","year":"2020","unstructured":"Htut TW, Thein KZ, Lawrie A, Tighe J, Preston G. Efficacy of daratumumab combination regimen in patients with multiple myeloma: a combined analysis of phase III randomized controlled trials. EJHaem. 2020;1:262\u20136.","journal-title":"EJHaem"},{"key":"1253_CR45","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8:5993\u20136002.","journal-title":"Blood Adv"},{"key":"1253_CR46","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers16172938","volume":"16","author":"B Paul","year":"2024","unstructured":"Paul B, Anwer F, Raza S, Mammadzadeh A, Khasawneh B, Shatnawi S, et al. Comparative meta-analysis of triplet vs. quadruplet induction regimens in newly diagnosed, treatment na\u00efve, multiple myeloma. Cancers. 2024;16:2938.","journal-title":"Cancers"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01253-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:37:45Z","timestamp":1741898265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01253-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JTDSF reported receiving honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Johnson & Johnson, Novartis, and Sanofi. LOC reported receiving honoraria from Johnson & Johnson. EQC reported receiving research funding from Johnson & Johnson and honoraria from Amgen, BMS, Johnson & Johnson, Sanofi, GSK, and Takeda. VH reported receiving honoraria from BMS, GSK, Johnson & Johnson, Regeneron, Sanofi, Takeda, Amgen, and AbbVie. AM reported receiving honoraria from Johnson & Johnson, BMS, Sanofi, Takeda, Pfizer, and Amgen. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}